Reading a Peptide Study: How to Spot Weak Evidence

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

Picture a patient sliding her phone across my desk and saying, "Doctor, this says it was proven in a study." The screenshot shows a bold headline, a glowing quote, and a link to something that looks like science. It takes me about ninety seconds to find the problem. The study was in rats. The headline quietly dropped that part. (This is a composite of conversations I've had, not one specific patient.)

I'm Dr. Farhan Abdullah, and at Magnolia Functional Wellness here in Southlake, some version of that conversation comes up fairly often. People aren't gullible. They're busy, they're hopeful, and the internet is very good at packaging a weak result so it looks like a strong one. So let's talk about how to read a study the way I do, especially when the topic is peptide medications.

Start With Who Was Studied

Before I look at a single result, I ask one question: who were the participants? A study in mice tells me something about mice. A study in cells in a dish tells me what happens in a dish. Neither tells me what happens in a 52-year-old woman with a thyroid history and a busy calendar.

That sounds obvious. It isn't, because the language gets slippery. "Shown to improve healing" can mean it improved healing in a rodent tendon. "Clinically studied" can mean twelve people, no comparison group, and a company that sells the product. When I read a claim, I hunt for the population in the first paragraph of the abstract. If I can't find humans in it, I stop treating the claim as a medical finding.

Even when the participants are human, the match matters. A trial in adults with obesity and established heart disease doesn't automatically apply to a healthy person who wants to lose fifteen pounds before a wedding. The result may still be relevant. It just isn't a guarantee, and a good clinician says so.

Randomized, Blinded, and Compared to Something

Here's the structure I trust most: people are randomly assigned to treatment or placebo, neither the patients nor the investigators know who got what, and the groups are followed for long enough that something real can happen. That's a randomized, double-blind, placebo-controlled trial.

Why does each piece matter? Randomization keeps the groups similar, so a difference between them is more likely to come from the treatment. Blinding keeps expectations from leaking into the measurements. A comparison group tells you what would have happened anyway, and in weight and symptom studies, "anyway" is a surprisingly large number. People who join a study tend to eat better, move more, and feel more hopeful, even on placebo.

A before-and-after report with no comparison group can't separate the treatment from all of that. When a clinic tells you that its patients lost an average of some impressive number, ask a follow-up question. Compared to whom? Measured how? Out of how many people who started?

The large semaglutide trial in adults with overweight or obesity, published in the New England Journal of Medicine in 2021 by Wilding and colleagues, is a good example of the structure I'm describing. It randomized adults to a once-weekly injection or a comparison group, alongside lifestyle support, and followed them for more than a year. You can disagree with how people use the findings. You can't say the design was vague.

Hard Outcomes Beat Convenient Ones

Next I look at what the researchers measured. Some endpoints are hard: heart attack, stroke, death, hospitalization. Others are surrogate markers, like a lab value or a score on a questionnaire. Surrogates are useful, and I order plenty of them. But a number moving in the right direction doesn't always mean a patient does better.

The cleanest recent example in peptide medicine is the SELECT trial. Lincoff and colleagues, writing in the New England Journal of Medicine in 2023, ran a multicenter, double-blind, randomized, placebo-controlled, event-driven trial. They enrolled people 45 or older with preexisting cardiovascular disease and a BMI of 27 or higher, but no diabetes, and they counted cardiovascular events. That's a hard outcome in a specific population, which is exactly why it carries weight.

Compare that with a post that says a product "supports cardiovascular wellness" because a blood marker shifted in a small group over eight weeks. Both are technically about the heart. They are not remotely the same level of evidence.

One more habit: I check whether the main result was the thing the study was designed to find. Trials declare a primary endpoint up front. If the headline comes from a secondary or subgroup analysis, that's a hint to slow down. Slice any dataset enough ways and something will look impressive by chance.

Watch for the Words "Exploratory" and "Post Hoc"

These two words show up in the methods section, and they change how much a result should move you. An exploratory analysis is a look around, not a test of a prediction. A post hoc analysis was decided after the data came in. Both can generate good questions. Neither should be sold as an answer.

I like the semaglutide withdrawal paper for this reason. In the STEP 1 extension, Wilding and colleagues reported in Diabetes, Obesity and Metabolism in 2022 on weight regain and cardiometabolic changes after treatment was stopped. The extension followed a representative subset of the participants, and the authors state plainly that all analyses in the extension were exploratory. That honesty is the model. It tells me the findings are worth taking seriously, and also worth not over-reading.

It also happens to be useful in the exam room. Patients often ask what happens if they stop. I can tell them there is real trial data on that question, and I can tell them the data came from a subset and was exploratory. A clinic that never mentions the limits of its evidence is giving you marketing, not medicine.

Size of the Effect and the Fine Print Around It

A result can be real and still not matter much. Statistical significance only tells you that a difference probably isn't a fluke. It says nothing about whether the difference is big enough to change your life. A treatment can produce a "significant" improvement of a few tenths of a point on a symptom scale, and you'd never feel it on a Tuesday morning.

So I look for the effect size, and I look for the confidence interval around it. A wide interval means the study couldn't pin the number down, which usually happens when the sample is small. A narrow one means the estimate is steadier. If a write-up reports only a p-value and never says how much anything changed, I get suspicious.

I also pay attention to relative versus absolute numbers. "Cuts risk by 50 percent" sounds dramatic. If the risk went from two in a thousand to one in a thousand, the absolute change is a single person in a thousand. That might still be worth it for a serious outcome, and I'm not dismissing it. I just want you to see both numbers, because a marketer will usually show you only the bigger one.

Finally, ask about dropouts. If a third of the participants left before the end, the people who remained may not look like the people who started. Good papers report this openly and explain how they handled it. Weak ones bury it, or skip it.

Follow the Money, Then Follow the Replication

Funding doesn't automatically invalidate a study. Many of the best drug trials are funded by manufacturers, because someone has to pay for thousands of participants. What funding should do is raise my attention. I read the limitations section more closely. I look for independent analyses, registry entries, and whether other groups found similar results.

Replication is the part that rarely makes it into a headline. One striking result is a hypothesis. Two or three consistent results from different teams, in different populations, start to look like knowledge. If a claim rests on a single small study, or on the same lab repeating itself, I treat it as unproven.

Then there's the testimonial problem. Before-and-after photos, five-star reviews, and a podcast guest who feels amazing are all stories. Stories are valuable for understanding what living with a condition is like. They are terrible evidence that a treatment works, because the people who didn't improve rarely get a microphone.

Here in North Texas, I hear people compare this to buying a truck. Nobody trusts a dealer who only quotes the best-case mileage, and nobody should trust a wellness claim that only quotes the best-case result. Ask for the whole sticker, including the fine print.

A Quick Checklist You Can Use Tonight

If you only remember a handful of things, make it these:

• Were the participants people like you, or animals and cells?
• Was there a randomized comparison group, and was it blinded?
• Did the study measure something that matters to your life, or only a lab value?
• Is the claim from the primary result, or from an exploratory slice?
• Has anyone else found the same thing?
• Does the person selling it also run the study, and do they tell you the limits?

You don't need a medical degree to ask those questions. You just need permission to be a little skeptical, and I'm giving you that permission.

What This Looks Like at Magnolia

When a patient asks about a new therapy, I go through the same filter in front of them. If the evidence is strong, I'll say so. If it's thin, I'll say that too, and we'll talk about whether it belongs in their plan at all. That's a big part of how we decide what to offer at Magnolia Functional Wellness, and it's why our peptide therapy program is built around medications with human trial data behind them. If you're curious how the GLP-1 weight-management medications fit together, our physician-supervised GLP-1 guide walks through the basics.

The next time a headline tells you something was proven in a study, take a breath and read past it. Find the participants. Find the comparison group. Find the word "exploratory" if it's there. And if you want a second set of eyes, bring the article to your visit in Southlake. I'd rather spend ten minutes picking apart a bad study with you than ten months watching you pay for it.